Compare PKE & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | DRUG |
|---|---|---|
| Founded | 1954 | 2019 |
| Country | United States | United States |
| Employees | 125 | N/A |
| Industry | Military/Government/Technical | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.7M | 707.1M |
| IPO Year | 1994 | 2020 |
| Metric | PKE | DRUG |
|---|---|---|
| Price | $37.51 | $66.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $129.25 |
| AVG Volume (30 Days) | 412.0K | ★ 432.3K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 93.10 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $68.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.23 | $24.18 |
| 52 Week High | $39.55 | $123.75 |
| Indicator | PKE | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 61.05 | 45.96 |
| Support Level | $31.16 | $49.47 |
| Resistance Level | $38.20 | $70.23 |
| Average True Range (ATR) | 2.01 | 4.41 |
| MACD | 0.57 | 1.24 |
| Stochastic Oscillator | 73.09 | 61.06 |
Park Aerospace Corp is an aerospace company that develops and manufactures composite materials used to produce composite structures for the aerospace market. Its products include film adhesives, lightning strike protection materials, specialty ablative materials for rocket motors and nozzles, and materials for radome applications. The Company offers composite materials designed for hand lay-up and automated fiber placement (AFP) manufacturing applications, which are used in jet engines, large and regional transport aircraft, military aircraft, unmanned aerial vehicles (UAVs), business jets, general aviation aircraft, and rotary wing aircraft. It operates in North America, Asia, and Europe, with North America generating maximum revenue.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.